Skip to main content

Advertisement

SpringerLink
Log in

The expression and the tumor suppressor role of CLDN6 in colon cancer

  • Published:
Molecular and Cellular Biochemistry Aims and scope Submit manuscript

Abstract

As a member of the tight junction family, CLDN6 is a tumor suppressor in breast cancer, but its role in colon cancer is unknown. In this research, we aimed at revealing the function of CLDN6 in colon cancer. We found that colon cancer tissues lowly expressed CLDN6, and the expression of CLDN6 was negatively correlated with lymph node metastasis. Similarly, CLDN6 was lowly expressed in the colon cancer cell line SW1116, and overexpression of CLDN6 inhibited cell proliferation in vitro and in vivo. Consistently, the migration and invasion abilities of cells were significantly inhibited after CLDN6 overexpression. In addition, we demonstrated that CLDN6 may inhibit the migration and invasion abilities by activating the TYK2/STAT3 pathway. Therefore, our data indicated that CLDN6 acted as a tumor suppressor and had the potential to be regarded as a biomarker for the progression of colon cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

Data availability

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

References

  1. Dekker E, Tanis PJ, Vleugels JLA, Kasi PM, Wallace MB (2019) Colorectal cancer. Lancet 394:1467–1480. https://doi.org/10.1016/s0140-6736(19)32319-0

    Article  PubMed  Google Scholar 

  2. DeSantis CE, Lin CC, Mariotto AB, Siegel RL, Stein KD, Kramer JL, Alteri R, Robbins AS, Jemal A (2014) Cancer treatment and survivorship statistics, 2014. CA Cancer J Clin 64:252–271. https://doi.org/10.3322/caac.21235

    Article  PubMed  Google Scholar 

  3. Tabariès S, Siegel PM (2017) The role of claudins in cancer metastasis. Oncogene 36:1176–1190. https://doi.org/10.1038/onc.2016.289

    Article  PubMed  CAS  Google Scholar 

  4. Shen Z, Song W, Qian L, Zhu J, Li Y, Li M, Zhang T, Zhao W, Zhou Y, Yang X (2021) Effect of claudin 1 on cell proliferation, migration and apoptosis in human cervical squamous cell carcinoma. Oncol Rep 45:606–618. https://doi.org/10.3892/or.2020.7889

    Article  PubMed  CAS  Google Scholar 

  5. Zhang X, Ruan Y, Li Y, Lin D, Quan C (2015) Tight junction protein claudin-6 inhibits growth and induces the apoptosis of cervical carcinoma cells in vitro and in vivo. Med Oncol 32:148. https://doi.org/10.1007/s12032-015-0600-4

    Article  PubMed  CAS  Google Scholar 

  6. Lu YZ, Li Y, Zhang T, Han ST (2020) Claudin-6 is down-regulated in gastric cancer and its potential pathway. Cancer Biomark 28:329–340. https://doi.org/10.3233/cbm-201554

    Article  PubMed  CAS  Google Scholar 

  7. Tong H, Li T, Qiu W, Zhu Z (2019) Claudin-1 silencing increases sensitivity of liver cancer HepG2 cells to 5-fluorouracil by inhibiting autophagy. Oncol Lett 18:5709–5716. https://doi.org/10.3892/ol.2019.10967

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  8. Wu J, Gao F, Xu T, Li J, Hu Z, Wang C, Long Y, He X, Deng X, Ren D, Zhou B, Dai T (2020) CLDN1 induces autophagy to promote proliferation and metastasis of esophageal squamous carcinoma through AMPK/STAT1/ULK1 signaling. J Cell Physiol 235:2245–2259. https://doi.org/10.1002/jcp.29133

    Article  PubMed  CAS  Google Scholar 

  9. Song P, Li Y, Dong Y, Liang Y, Qu H, Qi D, Lu Y, Jin X, Guo Y, Jia Y, Wang X, Xu W, Quan C (2019) Estrogen receptor β inhibits breast cancer cells migration and invasion through CLDN6-mediated autophagy. J Exp Clin Cancer Res 38:354. https://doi.org/10.1186/s13046-019-1359-9

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  10. Visco ZR, Sfakianos G, Grenier C, Boudreau MH, Simpson S, Rodriguez I, Whitaker R, Yao DY, Berchuck A, Murphy SK, Huang Z (2021) Epigenetic regulation of Claudin-1 in the development of ovarian cancer recurrence and drug resistance. Front Oncol 11:620873. https://doi.org/10.3389/fonc.2021.620873

    Article  PubMed  PubMed Central  Google Scholar 

  11. Dhawan P, Singh AB, Deane NG, No Y, Shiou SR, Schmidt C, Neff J, Washington MK, Beauchamp RD (2005) Claudin-1 regulates cellular transformation and metastatic behavior in colon cancer. J Clin Investig 115:1765–1776. https://doi.org/10.1172/jci24543

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  12. Luan N, Chen Y, Li Q, Mu Y, Zhou Q, Ye X, Deng Q, Ling L, Wang J, Wang J (2021) TRF-20-M0NK5Y93 suppresses the metastasis of colon cancer cells by impairing the epithelial-to-mesenchymal transition through targeting Claudin-1. Am J Transl Res 13:124–142

    PubMed  PubMed Central  CAS  Google Scholar 

  13. Resnick MB, Konkin T, Routhier J, Sabo E, Pricolo VE (2005) Claudin-1 is a strong prognostic indicator in stage II colonic cancer: a tissue microarray study. Mod Pathol 18:511–518. https://doi.org/10.1038/modpathol.3800301

    Article  PubMed  CAS  Google Scholar 

  14. Ahmad R, Kumar B, Chen Z, Chen X, Müller D, Lele SM, Washington MK, Batra SK, Dhawan P, Singh AB (2017) Loss of claudin-3 expression induces IL6/gp130/Stat3 signaling to promote colon cancer malignancy by hyperactivating Wnt/β-catenin signaling. Oncogene 36:6592–6604. https://doi.org/10.1038/onc.2017.259

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  15. Oshima T, Kunisaki C, Yoshihara K, Yamada R, Yamamoto N, Sato T, Makino H, Yamagishi S, Nagano Y, Fujii S, Shiozawa M, Akaike M, Wada N, Rino Y, Masuda M, Tanaka K, Imada T (2008) Reduced expression of the claudin-7 gene correlates with venous invasion and liver metastasis in colorectal cancer. Oncol Rep 19:953–959

    PubMed  CAS  Google Scholar 

  16. Wöss K, Simonović N, Strobl B, Macho-Maschler S, Müller M (2019) TYK2: an upstream kinase of STATs in cancer. Cancers (Basel). https://doi.org/10.3390/cancers11111728

    Article  Google Scholar 

  17. Yu H, Lee H, Herrmann A, Buettner R, Jove R (2014) Revisiting STAT3 signalling in cancer: new and unexpected biological functions. Nat Rev Cancer 14:736–746. https://doi.org/10.1038/nrc3818

    Article  PubMed  CAS  Google Scholar 

  18. Avalle L, Camporeale A, Camperi A, Poli V (2017) STAT3 in cancer: a double edged sword. Cytokine 98:42–50. https://doi.org/10.1016/j.cyto.2017.03.018

    Article  PubMed  CAS  Google Scholar 

  19. Lin D, Guo Y, Li Y, Ruan Y, Zhang M, Jin X, Yang M, Lu Y, Song P, Zhao S, Dong B, Xie Y, Dang Q, Quan C (2017) Bioinformatic analysis reveals potential properties of human Claudin-6 regulation and functions. Oncol Rep 38:875–885. https://doi.org/10.3892/or.2017.5756

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  20. Sugimoto K, Ichikawa-Tomikawa N, Kashiwagi K, Endo C, Tanaka S, Sawada N, Watabe T, Higashi T, Chiba H (2019) Cell adhesion signals regulate the nuclear receptor activity. Proc Natl Acad Sci USA 116:24600–24609. https://doi.org/10.1073/pnas.1913346116

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  21. Yang M, Li Y, Ruan Y, Lu Y, Lin D, Xie Y, Dong B, Dang Q, Quan C (2018) CLDN6 enhances chemoresistance to ADM via AF-6/ERKs pathway in TNBC cell line MDAMB231. Mol Cell Biochem 443:169–180. https://doi.org/10.1007/s11010-017-3221-8

    Article  PubMed  CAS  Google Scholar 

  22. Guo Y, Lin D, Zhang M, Zhang X, Li Y, Yang R, Lu Y, Jin X, Yang M, Wang M, Zhao S, Quan C (2016) CLDN6-induced apoptosis via regulating ASK1-p38/JNK signaling in breast cancer MCF-7 cells. Int J Oncol 48:2435–2444. https://doi.org/10.3892/ijo.2016.3469

    Article  PubMed  CAS  Google Scholar 

  23. Yu S, Zhang Y, Li Q, Zhang Z, Zhao G, Xu J (2019) CLDN6 promotes tumor progression through the YAP1-snail1 axis in gastric cancer. Cell Death Dis 10:949. https://doi.org/10.1038/s41419-019-2168-y

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  24. Cao X, He GZ (2018) Knockdown of CLDN6 inhibits cell proliferation and migration via PI3K/AKT/mTOR signaling pathway in endometrial carcinoma cell line HEC-1-B. OncoTargets Ther 11:6351–6360. https://doi.org/10.2147/ott.S174618

    Article  CAS  Google Scholar 

  25. Lin Z, Zhang XW, Liu ZJ, Liu QH, Wang LP, Lu Y, Liu YY, Wang M, Yang ML, Jin XS, Quan CS (2013) The distinct expression patterns of claudin-2, -6, and -11 between human gastric neoplasms and adjacent non-neoplastic tissues. Diagn Pathol. https://doi.org/10.1186/1746-1596-8-133

    Article  PubMed  PubMed Central  Google Scholar 

  26. Wu Q, Liu Y, Ren Y, Xu X, Yu L, Li Y, Quan C (2010) Tight junction protein, claudin-6, downregulates the malignant phenotype of breast carcinoma. Eur J Cancer Prev 19:186–194. https://doi.org/10.1097/CEJ.0b013e328337210e

    Article  PubMed  CAS  Google Scholar 

  27. Kohmoto T, Masuda K, Shoda K, Takahashi R, Ujiro S, Tange S, Ichikawa D, Otsuji E, Imoto I (2020) Claudin-6 is a single prognostic marker and functions as a tumor-promoting gene in a subgroup of intestinal type gastric cancer. Gastric Cancer 23:403–417. https://doi.org/10.1007/s10120-019-01014-x

    Article  PubMed  CAS  Google Scholar 

  28. Micke P, Mattsson JS, Edlund K, Lohr M, Jirström K, Berglund A, Botling J, Rahnenfuehrer J, Marincevic M, Pontén F, Ekman S, Hengstler J, Wöll S, Sahin U, Türeci O (2014) Aberrantly activated claudin 6 and 18.2 as potential therapy targets in non-small-cell lung cancer. Int J Cancer 135:2206–2214. https://doi.org/10.1002/ijc.28857

    Article  PubMed  CAS  Google Scholar 

  29. Birks DK, Kleinschmidt-DeMasters BK, Donson AM, Barton VN, McNatt SA, Foreman NK, Handler MH (2010) Claudin 6 is a positive marker for atypical teratoid/rhabdoid tumors. Brain Pathol 20:140–150. https://doi.org/10.1111/j.1750-3639.2008.00255.x

    Article  PubMed  CAS  Google Scholar 

  30. Kong FE, Li GM, Tang YQ, Xi SY, Loong JHC, Li MM, Li HL, Cheng W, Zhu WJ, Mo JQ, Gong YF, Tang H, Zhao Y, Zhang Y, Ma S, Guan XY, Ma NF, Xie MB, Liu M (2021) Targeting tumor lineage plasticity in hepatocellular carcinoma using an anti-CLDN6 antibody-drug conjugate. Sci Transl Med. https://doi.org/10.1126/scitranslmed.abb6282

    Article  PubMed  PubMed Central  Google Scholar 

  31. Liu Y, Jin X, Li Y, Ruan Y, Lu Y, Yang M, Lin D, Song P, Guo Y, Zhao S, Dong B, Xie Y, Dang Q, Quan C (2016) DNA methylation of claudin-6 promotes breast cancer cell migration and invasion by recruiting MeCP2 and deacetylating H3Ac and H4Ac. J Exp Clin Cancer Res 35:120. https://doi.org/10.1186/s13046-016-0396-x

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  32. Lu Y, Wang L, Li H, Li Y, Ruan Y, Lin D, Yang M, Jin X, Guo Y, Zhang X, Quan C (2017) SMAD2 inactivation inhibits CLDN6 methylation to suppress migration and invasion of breast cancer cells. Int J Mol Sci. https://doi.org/10.3390/ijms18091863

    Article  PubMed  PubMed Central  Google Scholar 

  33. O’Shea JJ, Schwartz DM, Villarino AV, Gadina M, McInnes IB, Laurence A (2015) The JAK-STAT pathway: impact on human disease and therapeutic intervention. Annu Rev Med 66:311–328. https://doi.org/10.1146/annurev-med-051113-024537

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  34. Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144:646–674. https://doi.org/10.1016/j.cell.2011.02.013

    Article  PubMed  CAS  Google Scholar 

  35. Ubel C, Mousset S, Trufa D, Sirbu H, Finotto S (2013) Establishing the role of tyrosine kinase 2 in cancer. Oncoimmunology 2:e22840. https://doi.org/10.4161/onci.22840

    Article  PubMed  PubMed Central  Google Scholar 

  36. Ide H, Nakagawa T, Terado Y, Kamiyama Y, Muto S, Horie S (2008) Tyk2 expression and its signaling enhances the invasiveness of prostate cancer cells. Biochem Biophys Res Commun 369:292–296. https://doi.org/10.1016/j.bbrc.2007.08.160

    Article  PubMed  CAS  Google Scholar 

  37. Muller S, Chen Y, Ginter T, Schafer C, Buchwald M, Schmitz LM, Klitzsch J, Schutz A, Haitel A, Schmid K, Moriggl R, Kenner L, Friedrich K, Haan C, Petersen I, Heinzel T, Kramer OH (2014) SIAH2 antagonizes TYK2-STAT3 signaling in lung carcinoma cells. Oncotarget 5:3184–3196. https://doi.org/10.18632/oncotarget.1899

    Article  PubMed  PubMed Central  Google Scholar 

  38. Herrmann A, Lahtz C, Nagao T, Song JY, Chan WC, Lee H, Yue C, Look T, Mulfarth R, Li W, Jenkins K, Williams J, Budde LE, Forman S, Kwak L, Blankenstein T, Yu H (2017) CTLA4 promotes Tyk2-STAT3-dependent B-cell oncogenicity. Cancer Res 77:5118–5128. https://doi.org/10.1158/0008-5472.CAN-16-0342

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  39. Liu H, Wang M, Liang N, Guan L (2019) Claudin-9 enhances the metastatic potential of hepatocytes via Tyk2/Stat3 signaling. Turk J Gastroenterol 30:722–731. https://doi.org/10.5152/tjg.2019.18513

    Article  PubMed  PubMed Central  Google Scholar 

  40. Sun L, Feng L, Cui J (2018) Increased expression of claudin-17 promotes a malignant phenotype in hepatocyte via Tyk2/Stat3 signaling and is associated with poor prognosis in patients with hepatocellular carcinoma. Diagn Pathol 13:72. https://doi.org/10.1186/s13000-018-0749-1

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  41. Bekki H, Kohashi K, Yamada Y, Iura K, Ishii T, Maekawa A, Otsuka H, Yamamoto H, Hakozaki M, Nabeshima K, Iwamoto Y, Oda Y (2017) Phosphorylation of STAT3 in undifferentiated pleomorphic sarcoma is correlated with a favorable prognosis. Pathobiology 84:161–169. https://doi.org/10.1159/000448524

    Article  PubMed  CAS  Google Scholar 

  42. Wu P, Wu D, Zhao L, Huang L, Shen G, Huang J, Chai Y (2016) Prognostic role of STAT3 in solid tumors: a systematic review and meta-analysis. Oncotarget 7:19863–19883. https://doi.org/10.18632/oncotarget.7887

    Article  PubMed  PubMed Central  Google Scholar 

  43. Nielsen M, Kaltoft K, Nordahl M, Röpke C, Geisler C, Mustelin T, Dobson P, Svejgaard A, Odum N (1997) Constitutive activation of a slowly migrating isoform of Stat3 in mycosis fungoides: tyrphostin AG490 inhibits Stat3 activation and growth of mycosis fungoides tumor cell lines. Proc Natl Acad Sci USA 94:6764–6769. https://doi.org/10.1073/pnas.94.13.6764

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  44. Meydan N, Grunberger T, Dadi H, Shahar M, Arpaia E, Lapidot Z, Leeder JS, Freedman M, Cohen A, Gazit A, Levitzki A, Roifman CM (1996) Inhibition of acute lymphoblastic leukaemia by a Jak-2 inhibitor. Nature 379:645–648. https://doi.org/10.1038/379645a0

    Article  PubMed  CAS  Google Scholar 

  45. Sanda T, Tyner JW, Gutierrez A, Ngo VN, Glover J, Chang BH, Yost A, Ma W, Fleischman AG, Zhou W, Yang Y, Kleppe M, Ahn Y, Tatarek J, Kelliher MA, Neuberg DS, Levine RL, Moriggl R, Müller M, Gray NS, Jamieson CH, Weng AP, Staudt LM, Druker BJ, Look AT (2013) TYK2-STAT1-BCL2 pathway dependence in T-cell acute lymphoblastic leukemia. Cancer Discov 3:564–577. https://doi.org/10.1158/2159-8290.Cd-12-0504

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  46. De Vos J, Jourdan M, Tarte K, Jasmin C, Klein B (2000) JAK2 tyrosine kinase inhibitor tyrphostin AG490 downregulates the mitogen-activated protein kinase (MAPK) and signal transducer and activator of transcription (STAT) pathways and induces apoptosis in myeloma cells. Br J Haematol 109:823–828. https://doi.org/10.1046/j.1365-2141.2000.02127.x

    Article  PubMed  Google Scholar 

  47. Zhang J, Liu C, You G (2018) AG490, a JAK2-specific inhibitor, downregulates the expression and activity of organic anion transporter-3. J Pharmacol Sci 136:142–148. https://doi.org/10.1016/j.jphs.2018.01.006

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  48. Fan Z, Zhang W, Cao Q, Zou L, Fan X, Qi C, Yan Y, Song B, Wu B (2022) JAK2/STAT3 pathway regulates microglia polarization involved in hippocampal inflammatory damage due to acute paraquat exposure. Ecotoxicol Environ Saf 234:113372. https://doi.org/10.1016/j.ecoenv.2022.113372

    Article  PubMed  CAS  Google Scholar 

  49. Tait Wojno ED, Hunter CA, Stumhofer JS (2019) the immunobiology of the interleukin-12 family: room for discovery. Immunity 50:851–870. https://doi.org/10.1016/j.immuni.2019.03.011

    Article  PubMed  CAS  Google Scholar 

Download references

Funding

This work was supported by the National Natural Science Foundation of China [Grant Numbers 81772816] and the Natural Science Foundation of Jilin Province [Grant Numbers 20210101329JC].

Author information

Authors and Affiliations

  1. The Key Laboratory of Pathobiology, Ministry of Education, College of Basic Medical Sciences, Jilin University, 126 Xinmin Avenue, Changchun, 130021, Jilin, People’s Republic of China

    Huinan Qu, Min Wang, Miaomiao Wang, Yuanyuan Liu & Chengshi Quan

Authors
  1. Huinan Qu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Min Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Miaomiao Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Yuanyuan Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Chengshi Quan
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

The first draft of the manuscript was written by HQ. Cell and animal experiments, data analysis were performed by MW. Molecular biology experiments were performed by MW. Immunohistochemistry experiments were performed by YL. Study design, funding acquisition, and supervision were completed by CQ.

Corresponding author

Correspondence to Chengshi Quan.

Ethics declarations

Conflict of interest

The authors have no relevant financial or non-financial interests to disclose.

Ethical approval

Tumor tissues were obtained from the Eastern Division of the First Hospital of Jilin University. This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the Ethics Committee of Jilin University and informed consent was obtained from all patients. All animal experiments and their care were approved by the Experimental Animal Ethical Committee of Jilin University and were carried out following relevant institution guidelines.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Qu, H., Wang, M., Wang, M. et al. The expression and the tumor suppressor role of CLDN6 in colon cancer. Mol Cell Biochem 477, 2883–2893 (2022). https://doi.org/10.1007/s11010-022-04450-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11010-022-04450-z

Keywords

Search

Navigation